JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Scope & Guideline
Pioneering advancements in cardiovascular therapeutics.
Introduction
Aims and Scopes
- Pharmacological Interventions for Cardiovascular Diseases:
The journal emphasizes studies on various pharmacological agents used to treat cardiovascular diseases, including novel therapies and existing medications, assessing their safety and efficacy. - Clinical Outcomes and Real-World Evidence:
Research that evaluates the outcomes of cardiovascular treatments in clinical practice, including observational studies and real-world data analyses, is a core focus. - Mechanistic Studies in Cardiovascular Pharmacology:
Investigations into the underlying mechanisms of action of cardiovascular drugs, including molecular and cellular pathways, are regularly featured. - Therapeutic Innovations and Trials:
The journal places a strong emphasis on clinical trials and innovative therapeutic approaches, including combination therapies and new drug formulations. - Impact of Comorbidities on Cardiovascular Treatment:
Research examining how comorbid conditions (e.g., diabetes, chronic kidney disease) affect cardiovascular treatment outcomes is a prominent theme.
Trending and Emerging
- SGLT2 Inhibitors and Heart Failure:
There is a growing focus on the role of SGLT2 inhibitors in treating heart failure, especially in patients with diabetes, highlighting their multifaceted benefits. - Personalized Medicine and Genotyping:
Emerging studies emphasize the importance of personalized medicine approaches, including genotyping for anticoagulant therapy, reflecting a trend towards individualized treatment strategies. - Impact of Lifestyle Factors on Cardiovascular Health:
Research exploring the effects of lifestyle factors—such as diet, physical activity, and smoking—on cardiovascular health and treatment outcomes is gaining traction. - Cardiovascular Effects of Novel Therapies:
An increased interest in the cardiovascular implications of non-cardiovascular drugs and therapies, including those used in cancer treatment, is evident in recent publications. - Integrative Approaches to Cardiovascular Care:
There is a notable trend towards integrative strategies combining pharmacological and non-pharmacological interventions, emphasizing holistic patient management.
Declining or Waning
- Traditional Antihypertensive Agents:
Research focusing solely on traditional antihypertensive medications has decreased, as newer agents and combination therapies are gaining prominence. - Static Observational Studies:
The prevalence of static observational studies without innovative designs or significant clinical implications appears to be declining, as the journal increasingly favors studies with robust methodologies and real-world applications. - Basic Science without Clinical Relevance:
Papers focusing solely on basic science aspects of cardiovascular pharmacology, lacking direct clinical relevance or application, have been published less frequently.
Similar Journals
PROGRESS IN CARDIOVASCULAR DISEASES
Elevating Standards in Cardiovascular ResearchPROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.
Archives of Cardiovascular Diseases
Pioneering research and collaboration in cardiology.The Archives of Cardiovascular Diseases, published by Elsevier Masson, stands as a leading journal in the field of cardiology and cardiovascular medicine, with an impressive impact factor that underscores its relevance and influence. This esteemed journal, recognized in the Q2 category for both cardiology and miscellaneous medicine, aims to disseminate groundbreaking research, innovative methodologies, and clinical advancements that can shape the future of cardiovascular health. With its diverse array of open access options, researchers and students alike have the ability to engage with high-quality content, ensuring that cutting-edge findings are accessible globally. Since its inception in 2008, the journal has actively contributed to the advancement of knowledge in cardiovascular diseases, fostering collaboration among clinicians, researchers, and educators. Headquartered in Paris, France, Archives of Cardiovascular Diseases remains committed to enhancing our understanding of cardiovascular health and improving patient outcomes worldwide.
American Journal of Cardiovascular Drugs
Exploring Innovations in Cardiovascular TherapyAmerican Journal of Cardiovascular Drugs, published by ADIS INT LTD, is a premier peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. With an ISSN of 1175-3277 and an E-ISSN of 1179-187X, this esteemed journal has established itself as a crucial platform for disseminating high-quality research since its inception in 2001. It holds a significant position in its domain, ranking in the second quartile (Q2) across several categories including Cardiology, Medicine (miscellaneous), and Pharmacology (medical) for the year 2023. With its Scopus ranks placing it in the 81st percentile for Cardiology and 77th percentile for Pharmacology, the journal is highly regarded among professionals, researchers, and students alike. While it is not an open-access journal, its comprehensive articles and systematic reviews provide an in-depth exploration of cardiovascular drug therapy, therapeutic advancements, and clinical practices, making it an invaluable resource for anyone invested in the future of cardiovascular health.
Minerva Cardiology and Angiology
Pioneering insights in cardiovascular medicine.Minerva Cardiology and Angiology, published by EDIZIONI MINERVA MEDICA, is a prominent journal in the field of cardiology and cardiovascular medicine, with an ISSN of 2724-5683 and E-ISSN of 2724-5772. Established in 2021, this journal aims to foster the dissemination of cutting-edge research, clinical practice guidelines, and innovative methodologies relevant to cardiovascular health. As of 2023, it holds a commendable Q3 quartile rank in its category, reflecting its growing influence within the scientific community. The journal is indexed in Scopus, where it ranks #221 out of 387 in its field, placing it in the 43rd percentile overall. Although it currently does not offer Open Access options, articles published in Minerva Cardiology and Angiology contribute significantly to ongoing discussions and advancements in heart and vascular health. The journal serves as an invaluable resource for researchers, healthcare professionals, and students seeking to stay informed on the latest developments in cardiology.
TRENDS IN CARDIOVASCULAR MEDICINE
Transforming Research into Clinical ExcellenceTRENDS IN CARDIOVASCULAR MEDICINE, published by Elsevier Science London, stands at the forefront of the cardiology field, with a commendable Q1 ranking in the category of Cardiology and Cardiovascular Medicine. Since its inception in 1991, this esteemed journal has provided a vital platform for disseminating cutting-edge research and innovative clinical practices, reflecting the dynamic developments in cardiovascular health. With an impact factor positioning it among the top 3% in its category, TRENDS IN CARDIOVASCULAR MEDICINE is essential reading for researchers, healthcare professionals, and students pursuing the latest advancements and evidence-based approaches in cardiology. Although this journal does not currently operate under an open-access model, its rich array of content encompasses a variety of topics from clinical studies to reviews, ensuring readers stay informed on the pivotal trends that shape cardiovascular medicine. This commitment to excellence underscores the journal's role as a premier resource for anyone dedicated to improving cardiovascular health.
Cardiovascular Diagnosis and Therapy
Transforming Cardiovascular Health with Cutting-Edge DiscoveriesCardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.
Nepalese Heart Journal
Illuminating the Path to Cardiovascular WellnessNepalese Heart Journal, published by the CARDIAC SOC NEPAL, serves as a premier platform for disseminating knowledge in the field of cardiology and cardiovascular health. With an ISSN of 2091-2978, this journal aims to bridge the gap between researchers, clinicians, and academicians by presenting high-quality, peer-reviewed articles that address clinical practices, innovative research, and emerging trends in heart disease management, especially within the context of Nepal and the surrounding region. Although it operates under a traditional publishing model, its commitment to excellence aids in reinforcing the scientific discourse in an area critical to public health. The journal is a valuable resource for professionals and students alike who are focused on advancing their understanding of cardiology and its implications for health policy and practice. Exploring the intersections of local challenges and global advancements in heart health, the Nepalese Heart Journal is poised to contribute meaningfully to the evolving landscape of cardiovascular research.
Current Vascular Pharmacology
Innovating Drug Development for Cardiovascular CareCurrent Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.
Expert Review of Clinical Pharmacology
Transforming patient care with expert pharmacological reviews.Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.
VASCULAR PHARMACOLOGY
Illuminating molecular pathways in vascular pharmacology.Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.